SEC Comment Letter 0000000000-24-003700 to Cogent Biosciences, Inc. (COGT) (CIK 0001622229) (COGT)
Cogent Biosciences, Inc. (COGT) (CIK 0001622229)
Date: April 5, 2024 · CIK: 0001622229 · Accession: 0000000000-24-003700
AI Filing Summary & Sentiment
File numbers found in text: 333-278382
Letter
United States securities and exchange commission logo April 5, 2024 Andrew Robbins Chief Executive Officer Cogent Biosciences, Inc. 275 Wyman Street, 3rd Floor Waltham, MA 02451 Re:Cogent Biosciences, Inc. Registration Statement on Form S-3 Filed March 29, 2024 File No. 333-278382 Dear Andrew Robbins: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ryan Murr, Esq.
Show Raw Text
United States securities and exchange commission logo
April 5, 2024
Andrew Robbins
Chief Executive Officer
Cogent Biosciences, Inc.
275 Wyman Street, 3rd Floor
Waltham, MA 02451
Re:Cogent Biosciences, Inc.
Registration Statement on Form S-3
Filed March 29, 2024
File No. 333-278382
Dear Andrew Robbins:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Ryan Murr, Esq.